TY - JOUR
T1 - Antifibrotic therapiesemerging biomarkers as treatment end points
AU - Talwalkar, Jayant A.
PY - 2010/1
Y1 - 2010/1
N2 - The emergence of novel pharmacologic therapies for hepatic fibrosis holds promise for the management of this condition. Furthermore, novel, biological indicesin addition to liver biopsymay improve our ability to assess the unique pharmacological effects generated by these agents. This article will attempt to highlight the potential for emerging biomarkers to serve as end points in clinical studies that target salient features of hepatic fibrogenesis.
AB - The emergence of novel pharmacologic therapies for hepatic fibrosis holds promise for the management of this condition. Furthermore, novel, biological indicesin addition to liver biopsymay improve our ability to assess the unique pharmacological effects generated by these agents. This article will attempt to highlight the potential for emerging biomarkers to serve as end points in clinical studies that target salient features of hepatic fibrogenesis.
UR - http://www.scopus.com/inward/record.url?scp=74949133886&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=74949133886&partnerID=8YFLogxK
U2 - 10.1038/nrgastro.2009.197
DO - 10.1038/nrgastro.2009.197
M3 - Comment/debate
C2 - 20051972
AN - SCOPUS:74949133886
SN - 1759-5045
VL - 7
SP - 59
EP - 61
JO - Nature Reviews Gastroenterology and Hepatology
JF - Nature Reviews Gastroenterology and Hepatology
IS - 1
ER -